Literature DB >> 10658237

Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution.

A Jäppinen1, H Kokki, T J Naaranlahti, A S Rasi.   

Abstract

Combinations of opioids and adjuvant drug solutions are often used in clinical practice while little information is available on their microbiological or chemical stability. Currently there are no commercially available, prepacked, ready-to-use epidural or subcutaneous mixtures. Thus, epidural and subcutaneous analgesic mixtures must be prepared in the pharmacy on an as-needed basis. Such mixtures are typically used for the treatment of severe pain in cancer patients. The aim of this study was to investigate the microbiological and chemical stability of a buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. A high performance liquid chromatographic (HPLC) method and pH-meter were used to conduct the analyses. Antimicrobial activity of each component was studied by an agar dilution method. According to the results from the chemical and microbiological stability studies, this mixture can be stored in polypropylene (PP) syringes and polyvinyl chloride (PVC) medication cassettes for at least 30 days at either 21 degrees C or 4 degrees C, and for 16 days in PP syringes at 36 degrees C, and for 9 days in PVC medication cassettes at 36 degrees C.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10658237     DOI: 10.1023/a:1008771621812

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  7 in total

Review 1.  Pharmacologic treatment of cancer pain.

Authors:  M H Levy
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

2.  Practice guidelines for cancer pain management. A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section.

Authors: 
Journal:  Anesthesiology       Date:  1996-05       Impact factor: 7.892

3.  A comparison of the antibacterial properties of six local analgesic agents.

Authors:  S Zaidi; T E Healy
Journal:  Anaesthesia       Date:  1977-01       Impact factor: 6.955

Review 4.  The value of "multimodal" or "balanced analgesia" in postoperative pain treatment.

Authors:  H Kehlet; J B Dahl
Journal:  Anesth Analg       Date:  1993-11       Impact factor: 5.108

5.  Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study.

Authors:  E Kalso; T Heiskanen; M Rantio; P H Rosenberg; A Vainio
Journal:  Pain       Date:  1996-10       Impact factor: 6.961

Review 6.  Spinal antinociception: clinical aspects.

Authors:  N Rawal
Journal:  Ann Med       Date:  1995-04       Impact factor: 4.709

Review 7.  Epidural analgesia.

Authors:  R A Littrell
Journal:  Am J Hosp Pharm       Date:  1991-11
  7 in total
  4 in total

1.  Stability-indicating LC-MS Method for Determination of Stability of Extemporaneously Compounded Buprenorphine Oral Syringes for Neonatal Abstinence Syndrome.

Authors:  Ankit Rochani; Vinh Nguyen; Robin Becker; Walter Kraft; Gagan Kaushal
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

Review 2.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

3.  Effects of Time and Storage Conditions on the Chemical and Microbiologic Stability of Diluted Buprenorphine for Injection.

Authors:  Johnathan M DenHerder; Ralph L Reed; Jennifer L Sargent; Gerd Bobe; Jan F Stevens; Helen E Diggs
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-07-01       Impact factor: 1.232

Review 4.  The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review.

Authors:  James Baker; Andrew Dickman; Stephen Mason; John Ellershaw
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.